Stock Track | Medtide Soars 5.23% Intraday as Investor Enthusiasm Builds Following Hong Kong IPO

Stock Track06-30

Medtide Inc. (HKG:3880), a peptide-focused CRDMO, is experiencing a significant surge in its stock price during intraday trading on Monday. The company's shares are soaring 5.23%, marking a strong reversal from its initial performance at the market open.

This impressive rally comes on the heels of Medtide's recent initial public offering (IPO) in Hong Kong. The company successfully raised HK$428.8 million in net proceeds after pricing its shares at HK$30.60, the top end of the indicative price range. The IPO garnered substantial interest, with the Hong Kong public offer portion being 301.15 times oversubscribed, leading to a reallocation of shares from the international offering.

Despite opening slightly below its IPO price at HK$30.30 in early trading, investor sentiment appears to have shifted dramatically during the day. The strong intraday performance suggests growing confidence in Medtide's prospects and may reflect investors' positive reaction to the company's successful fundraising and the high demand seen during the IPO process. As the trading day progresses, market participants will be closely watching to see if this upward momentum can be sustained.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181216476?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 13:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181216476","market":"nz","top_or_hot":-1,"title":"Stock Track | Medtide Soars 5.23% Intraday as Investor Enthusiasm Builds Following Hong Kong IPO","media":"Stock Track","content":"<p>Medtide Inc. (HKG:3880), a peptide-focused CRDMO, is experiencing a significant surge in its stock price during intraday trading on Monday. The company's shares are soaring 5.23%, marking a strong reversal from its initial performance at the market open.</p>\n\n<p>This impressive rally comes on the heels of Medtide's recent initial public offering (IPO) in Hong Kong. The company successfully raised HK$428.8 million in net proceeds after pricing its shares at HK$30.60, the top end of the indicative price range. The IPO garnered substantial interest, with the Hong Kong public offer portion being 301.15 times oversubscribed, leading to a reallocation of shares from the international offering.</p>\n\n<p>Despite opening slightly below its IPO price at HK$30.30 in early trading, investor sentiment appears to have shifted dramatically during the day. The strong intraday performance suggests growing confidence in Medtide's prospects and may reflect investors' positive reaction to the company's successful fundraising and the high demand seen during the IPO process. As the trading day progresses, market participants will be closely watching to see if this upward momentum can be sustained.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Medtide Soars 5.23% Intraday as Investor Enthusiasm Builds Following Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Medtide Soars 5.23% Intraday as Investor Enthusiasm Builds Following Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-06-30 13:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Medtide Inc. (HKG:3880), a peptide-focused CRDMO, is experiencing a significant surge in its stock price during intraday trading on Monday. The company's shares are soaring 5.23%, marking a strong reversal from its initial performance at the market open.</p>\n\n<p>This impressive rally comes on the heels of Medtide's recent initial public offering (IPO) in Hong Kong. The company successfully raised HK$428.8 million in net proceeds after pricing its shares at HK$30.60, the top end of the indicative price range. The IPO garnered substantial interest, with the Hong Kong public offer portion being 301.15 times oversubscribed, leading to a reallocation of shares from the international offering.</p>\n\n<p>Despite opening slightly below its IPO price at HK$30.30 in early trading, investor sentiment appears to have shifted dramatically during the day. The strong intraday performance suggests growing confidence in Medtide's prospects and may reflect investors' positive reaction to the company's successful fundraising and the high demand seen during the IPO process. As the trading day progresses, market participants will be closely watching to see if this upward momentum can be sustained.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03880","symbol_name":"泰德医药","start_time":0,"source_url":"","article_id":"1181216476","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181216476","pubTimestamp":1751260007,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Medtide Inc. , a peptide-focused CRDMO, is experiencing a significant surge in its stock price during intraday trading on Monday. The company's shares are soaring 5.23%, marking a strong reversal from its initial performance at the market open.This impressive rally comes on the heels of Medtide's recent initial public offering  in Hong Kong. The company successfully raised HK$428.8 million in net proceeds after pricing its shares at HK$30.60, the top end of the indicative price range. The IPO ga","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03880":"泰德医药"},"translate_title":"香港IPO后投资者热情高涨，股票赛道Medtide盘中飙升5.23%","themeId":"6236850a5ccd706a69e00421affe9b09","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03880":1},"content_text":"Medtide Inc. (HKG:3880), a peptide-focused CRDMO, is experiencing a significant surge in its stock price during intraday trading on Monday. The company's shares are soaring 5.23%, marking a strong reversal from its initial performance at the market open.\nThis impressive rally comes on the heels of Medtide's recent initial public offering (IPO) in Hong Kong. The company successfully raised HK$428.8 million in net proceeds after pricing its shares at HK$30.60, the top end of the indicative price range. The IPO garnered substantial interest, with the Hong Kong public offer portion being 301.15 times oversubscribed, leading to a reallocation of shares from the international offering.\nDespite opening slightly below its IPO price at HK$30.30 in early trading, investor sentiment appears to have shifted dramatically during the day. The strong intraday performance suggests growing confidence in Medtide's prospects and may reflect investors' positive reaction to the company's successful fundraising and the high demand seen during the IPO process. As the trading day progresses, market participants will be closely watching to see if this upward momentum can be sustained.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181216476","isCrawlerRequest":true}